A Study to Evaluate the Pharmacodynamic Activity of E2082 in Adult Participants With Photosensitive Epilepsy

Summary

The primary purpose of the study is to assess pharmacodynamic (PD) activity of E2082 as measured by suppression of epileptic photoparoxysmal response (PPR) in the participant's most sensitive eye condition in participants with photosensitive epilepsy, compared to placebo.

Timeline

Start

2018-10-31

Primary completion

2019-06-18

Completion

2019-06-18

Outcome

Met primary endpoint

Stopped: “Safety Review”

registry analysis (superiority test); Treatment A: Placebo vs Treatment C: E2082 25 mg; LS Mean difference -4.17 (90% CI -6.35 to -1.99) NCT03686033 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	E2082	Unknown	2.5 mg	Oral
Subject	E2082	Unknown	25 mg	Oral
Subject	E2082	Unknown	40 mg	Oral

Indications